Syros Pharmaceuticals (SYRS) Stock Price, News & Analysis

Company Overview

Syros Pharmaceuticals, Inc. was a clinical-stage biopharmaceutical company focused on developing medicines that target gene control mechanisms involved in cancer and other serious diseases. The company used genomic and molecular biology research to identify patient populations most likely to respond to its investigational therapies.

Syros’ principal product candidate was tamibarotene, an oral, selective retinoic acid receptor alpha agonist investigated for the treatment of certain patients with acute myeloid leukemia and higher-risk myelodysplastic syndromes. Development of the therapy centered on identifying patients whose cancer cells express the RARA biomarker. The company also previously developed SY-5609, an investigational cyclin-dependent kinase 7 inhibitor, for oncology applications.

Founded in 2012 and headquartered in Cambridge, Massachusetts, Syros conducted its clinical-development activities primarily in the United States and worked with research and commercial partners to advance its programs. The company subsequently undertook a strategic review and began winding down operations, making its historical research and development activities more relevant than an active commercial product business.

Key Stats

• Today's Range: $0.0004 to $0.0004
• 50-Day Range: N/A
• 52-Week Range: $0.00 to $0.02
• Volume: 3,092 shs
• Average Volume: 15,495 shs
• Market Capitalization: $10.73 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Today: 11/09/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:SYRS
• CIK: 1556263
• Web: www.syros.com
• Phone: (617) 744-1340
• Fax: N/A
• Employees: 68
• Year Founded: 2012

Profitability

• EPS (Trailing Twelve Months): ($3.03)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$164.57 million
• Net Margins: N/A
• Pretax Margin: -25,275.20%
• Return on Equity: -3,369.56%
• Return on Assets: -97.04%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.25
• Quick Ratio: 2.25

Sales & Book Value

• Annual Sales: $386 thousand
• Price / Sales: 0.03
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.79 per share
• Price / Book: 0.00

Miscellaneous

• Outstanding Shares: 26,832,000
• Free Float: 23,542,000
• Market Cap: $10.73 thousand
• Optionable: No Data
• Beta: 1.31